Apellis Pharmaceuticals Inc (NASDAQ:APLS) has been given a consensus broker rating score of 1.00 (Strong Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. Four analysts have rated the stock with a strong buy rating.
Brokers have set a 1-year consensus price target of $32.50 for the company and are predicting that the company will post ($0.27) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Apellis Pharmaceuticals an industry rank of 187 out of 265 based on the ratings given to related companies.
A number of research firms recently commented on APLS. Evercore ISI began coverage on shares of Apellis Pharmaceuticals in a research report on Monday, December 4th. They issued an “outperform” rating on the stock. JPMorgan Chase & Co. began coverage on shares of Apellis Pharmaceuticals in a research report on Monday, December 4th. They issued an “overweight” rating and a $31.00 target price on the stock. B. Riley began coverage on shares of Apellis Pharmaceuticals in a research report on Thursday, February 8th. They issued a “buy” rating and a $27.00 target price on the stock. Finally, Citigroup began coverage on shares of Apellis Pharmaceuticals in a research report on Monday, December 4th. They issued a “buy” rating and a $23.00 target price on the stock.
Apellis Pharmaceuticals (APLS) traded up $2.83 during midday trading on Wednesday, hitting $25.23. 211,306 shares of the company were exchanged, compared to its average volume of 89,441. The stock has a market cap of $1,270.00 and a P/E ratio of -31.54. Apellis Pharmaceuticals has a 1 year low of $12.45 and a 1 year high of $25.59.
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.